Rhovac ApS Company
RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells.
Estimated Revenue:
$1M to $10M
Industry:
Peptides and Proteins
Investors Number:
1
Last Funding Date:
2019-08-22
Founded Date:
2008-01-01
Headquarters:
Hørsholm, Hovedstaden, Denmark
Total Funding:
2770912
Last Funding Type:
Grant
Employee Number:
11-50